生长激素释放激素 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-07. Numbers and descriptions here follow the published literature rather than marketing material.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Specifically, two dimers, one cyclic (C6H12O4, a tetroxane) and one open chain (C6H14O4), as well as an open dihydroperoxide monomer (C3H8O4), can also be formed; under a particular set of conditions of reagent and acid catalyst concentration, the cyclic trimer is the primary product. Under neutral conditions, the reaction is reported to produce the monomeric organic peroxide. A tetrameric form has also been described, under different catalytic conditions, albeit not without disputes and controversy. The most common route for nearly pure TATP is H2O2/acetone/HCl in 1:1:0.25 molar ratios, using 30% hydrogen peroxide. This product contains very little or none of DADP with some very small traces of chlorinated compounds. Product that contains large fraction of DADP can be obtained from 50% H2O2 using large amounts of concentrated sulfuric acid as catalyst or alternatively with 30% H2O2 and massive amounts of HCl as a catalyst. The product made by using hydrochloric acid is regarded as more stable than the one made using sulfuric acid. It is known that traces of sulfuric acid trapped inside the formed acetone peroxide crystals lead to instability. In fact, the trapped sulfuric acid can induce detonation at temperatures as low as 50 °C (122 °F). This is the most likely mechanism behind accidental explosions of acetone peroxide that occur during drying on heated surfaces. Organic peroxides in general are sensitive, dangerous explosives, and all forms of acetone peroxide are sensitive to initiation.
Angus Monfries (born 19 January 1987) is a former professional Australian rules footballer who played for the Essendon Football Club and Port Adelaide Football Club in the Australian Football League (AFL). Monfries played as a forward pocket or half forward.
To import or export, sell or offer for sale, supply—even gratuitously—transport, carry, keep in storage, store, administer, or in any way deliver for consumption any narcotic substance, without authorization or in violation of legal or regulatory provisions. This article rendered these drugs illegal and thus authorized police powers and regulatory bodies to impose sanctions on users and traffickers of illicit drugs. Even before their legal prohibition, narcotic drugs were already shrouded in prejudice—particularly racial prejudice, such as in the case of marijuana, which was nicknamed "Angola weed", because it was mainly used by adherents of Afro-Brazilian religions in their rituals. In 1973, when Brazil acceded to the Convention on Psychotropic Substances, the "war on drugs" shifted its approach; the new drug policies clearly defined the penalties and consequences associated with possessing, purchasing, or selling these substances. It was in the Brazilian state's interest to marginalize and prohibit narcotics, given that during the 1968 student marches against the military dictatorship, drugs had been used as a symbol of resistance against the regime—and, due to the lack of clear penalties, users faced neither prosecution nor punishment.
Several nucleoside analogues are used as antiviral or anticancer agents. The viral polymerase incorporates these compounds with non-canonical bases. These compounds are activated in the cells by being converted into nucleotides, they are administered as nucleosides since charged nucleotides cannot easily cross cell membranes.
All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for opioid use disorder in their practice if permitted by applicable state law. The Substance Abuse and Mental Health Services Administration encourages practitioners to treat patients within their practices who require treatment for a substance use disorder. Because it may now be prescribed much more readily out of an office setting (as opposed to methadone, which requires specialized centers), buprenorphine/naloxone allows people more access to this medication and more freedom of administration. It also thus comes with more risks in this vulnerable population. Buprenorphine/naloxone may be recommended for socially stable people who use opioids who cannot retrieve medications from a center daily, who have another condition requiring regular primary care visits, or who have jobs or daily lives that require they maintain all their faculties and cannot take a sedating medication. Buprenorphine/naloxone is also recommended over methadone for people at high risk of methadone toxicity, such as the elderly, those taking high doses of benzodiazepines or other sedating substances, concomitant alcohol use disorder, those with a lower level of opioid tolerance, and those at high risk of prolonged QT interval. It is also helpful to use the medication in combination with psychosocial support and counseling.
Sources: en.wikipedia.org
Aticaprant, also known by its developmental codes JNJ-67953964, CERC-501, and LY-2456302, is a κ-opioid receptor (KOR) antagonist which was under development for the treatment of major depressive disorder and other conditions. Aticaprant is taken orally. Side effects of aticaprant include itching, among others. Aticaprant acts as a selective antagonist of the KOR, the biological target of the endogenous opioid peptide dynorphin. The medication has decent selectivity for the KOR over the μ-opioid receptor (MOR) and other targets, a relatively long half-life of 30 to 40 hours, and readily crosses the blood–brain barrier to produce central effects. Aticaprant was originally developed by Eli Lilly, was under development by Cerecor for a time, and is now under development by Janssen Pharmaceuticals. In July 2022, it was in phase III clinical trials for major depressive disorder. In March 2025, Johnson & Johnson discontinued development of aticaprant for major depressive disorder due to lack of effectiveness in phase III trials. Aticaprant was also under development for the treatment of alcoholism, cocaine use disorder, and nicotine withdrawal, but development for these indications was discontinued as well.
=== Lifestyle === Weight loss is the most effective treatment for MASLD and MASH. A loss of 5% to 10% body weight is recommended and has shown regression of liver damage, with 10% to 40% weight loss completely reversing MASH without cirrhosis. A weight loss of greater than 10% was associated with the resolution of MASH in 90% of people in a biopsy-based study. A structured weight loss program helps people with MASLD lose more weight compared with advice alone. This type of program also leads to improvements in MASLD measured by blood tests, ultrasound, imaging, or liver biopsies. Although fibrosis improves with lifestyle interventions and weight loss, there is limited evidence for improvement in cirrhosis. A combination of improved diet and exercise, rather than either alone, appears to help manage MASFLD and reduce insulin resistance. Motivational support, such as with cognitive behavioral therapy, is helpful, as most people with MASLD do not perceive their condition as a disease, and thus have a low motivation to change. Higher-intensity behavioral weight loss therapies (diet and exercise combined) may produce greater weight loss than lower-intensity ones. A 2019 systematic review suggested updating the guidelines to recommend these therapies for MASLD management. Weight loss is associated with improvements in biomarkers, MASLD severity, and a lower risk of MASH, but its effect on long-term health is not known.
In contrast to these serotonin releasing agents however, mCPP does not appear to cause long-term serotonin depletion (a property thought to be related to serotonergic neurotoxicity). Trazodone's 5-HT2A receptor antagonism and weak serotonin reuptake inhibition form the basis of its common label as an antidepressant of the serotonin antagonist and reuptake inhibitor (SARI) type.
The Miami Herald reported on 2 October 2025 that sources said the US effort had "effectively shut down" the busy "Caribbean route" for estimated 2024 annual shipments of between 350 and 500 tons of cocaine coming from Venezuela. According to the Miami Herald, the campaign's "goal is financial: cutting off the drug revenue that sustains loyalty among Venezuela's senior military and police commanders, many of whom are accused of profiting directly from narcotrafficking." Trafficking through older air and land routes from Colombia are more costly than maritime shipments, and sources said that Venezuelan "cash flow from trafficking is under direct threat, and that puts the cohesion of the military elite at risk", with "authorities [turning] to heavier taxation and extortion of businesses to keep the state's security apparatus afloat." According to The Economist, "Few ... think drugs are the sole or even the main focus" of the operation, noting that fentanyl, the drug that causes the most deaths in the US, is almost entirely "synthesized in Mexico and trafficked north over land" and that "the hardware"—e.g. destroyers—"doesn't match the task" of drug policing.
Sources: en.wikipedia.org
=== Road freight === Transport by road is by far the most popular means of moving freight around South Africa. As of October 2025, over 85% of land freight in SA travels by road. For every ton of freight moved by rail, more than six tons is moved by road. Each year, almost 1 billion tons (984 million) of freight is transported along South Africa's road networks. This is an increase of over 50% over the period between 2010 and 2025. National roads in South Africa are administered by SANRAL, a state-owned company that reports to the Department of Transport. SANRAL is responsible for financing, managing, planning, developing, and maintaining the national road network. Municipalities also have control over and put funding into certain roadways. Certain avenues of private funding for roadways in South Africa also exist.
=== Liquid crystals, colloidal glasses, and hydrogels === Owed to their anisotropic shape and surface charge, nanocelluloses (mostly rigid CNCs) have a high excluded volume and self-assemble into cholesteric liquid crystals beyond a critical volume fraction. Nanocellulose liquid crystals are left-handed due to the right-handed twist on particle level. Nanocellulose phase behavior is susceptible to ionic charge screening. An increase in ionic strength induces the arrest of nanocellulose dispersions into attractive glasses. At further increasing ionic strength, nanocelluloses aggregate into hydrogels. The interactions within nanocelluloses are weak and reversible, wherefore nanocellulose suspensions and hydrogels are self-healing and may be applied as injectable materials or 3D printing inks.
== Function == While SARM1 has been studied as a Toll-like receptor adaptor protein in an immune context, its most well-studied function in mammals is as a sensor of metabolic stress and an executioner of neuronal cell body and axon death. Because SARM1 is highly expressed in the nervous system, most studies of SARM1 focus on neuron degeneration, but some SARM1 can be found in other tissues, notably macrophages and T cells. By generating cADPR or NAADP, SARM1 may function as a Ca2+-signaling enzyme similar to CD38.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.